The power of the platform

We have developed a pipeline of novel small molecule compounds targeting key Rho GTPases by interrogating the biology of their deregulation with our drug discovery platform.

The foundation of our proprietary Rho GTPase platform is the customized suite of biochemical and cellular assays we have developed for Rac1 wild type and several variants and Cdc42.  These assays inform our medicinal chemistry, structural biology, and computational modeling efforts for design and development of a diverse pipeline of Rac1 and Cdc42 inhibitors.